Other grades of this product :
| Product Name: | GS9620 | | Synonyms: | CS-925;GS 9620; GS9620;Vesatolimod;GS9620, >=98%;4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one;4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one;4-Amino-2-butoxy-8-[3-(1-pyrrolidinylmethyl)benzyl]-7,8-dihydro-6(5H)-pteridinone;GS 9620 | | CAS: | 1228585-88-3 | | MF: | C22H30N6O2 | | MW: | 410.51 | | EINECS: | | Product Categories: | API | | Mol File: | 1228585-88-3.mol |
| GS9620 Chemical Properties |
| density | 1.247±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (10 mg/ml) | | form | solid | | pka | 10.34±0.20(Predicted) | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| GS9620 Usage And Synthesis |
| Description | GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic infection and transiently activated HIV expressionex vivoin latently-infected peripheral blood mononuclear cells (PBMCs) from virally suppressed patients. Currently, GS-9620 is under clinical evaluation for treating chronic HBV infection and for reducing latent reservoirs in virally-suppressed HIV-infected patients.
| | References | Lopatin, U, et al. "Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist." Antiviral Therapy18.3(2013):409-18.
Gane, E. J., et al. "The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection." Journal of Hepatology63.2(2015):320.
Lanford, Robert E., et al. "GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees." Gastroenterology 144.7(2013):1508.
|
| GS9620 Preparation Products And Raw materials |
|